Currently three treatments are available for SMA patients – Onasemnogene abeparvovec-xioi (Zolgensma) a gene therapy for treating children below two years of age, Nusinersen (Spinraza ...

SMA treatment in India currently faces significant hurdles. Among the three globally available treatments—gene therapy Zolgensma, Spinraza (Nusinersen), and Evrysdi (Risdiplam)—only Evrysdi is ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

There are at least three treatments available for SMA patients - Onasemnogene abeparvovec-xioi (Zolgensma), a gene therapy for treating children below two years of age, Nusinersen (Spinraza) is an ...

However, the eligible patient population indicated for Novartis' Zolgensma is limited ... s once-quarterly IT administration of Spinraza (nusinersen) and Roche’s once-daily Evrysdi (risdiplam).

Novartis’ Zolgensma, an IV formulation of onasemnogene ... compared to Biogen’s once-quarterly IT administration of Spinraza (nusinersen) and Roche’s once-daily Evrysdi (risdiplam).

Among the three globally available treatments—gene therapy Zolgensma, Spinraza (Nusinersen), and Evrysdi (Risdiplam)—only Evrysdi is approved for use in the country. “It is important to note ...